Temozolomide treats certain brain cancers; current headlines flag health-system pressure and reviews of prescribing patterns surrounding its use.
A BBC and other outlets reveal concerns over prolonged cancer treatment, delayed surgeries, and oversight failures across multiple NHS trusts. New reviews show patients were subjected to extended temozolomide therapy with little evidence of benefit, while cancer wait-time targets faltered and leadership faces accountability questions.
[Synopsis here]